Market Closed -
Euronext Paris
11:35:28 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
5.56
EUR
|
-0.71%
|
|
+3.35%
|
+29.91%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
50.21
|
55.22
|
129
|
187.7
|
123.4
|
119.9
|
119.9
|
-
|
Enterprise Value (EV)
1 |
45.1
|
40.86
|
119.2
|
186.5
|
138.1
|
80.55
|
166.5
|
118.7
|
P/E ratio
|
9.71
x
|
-11.9
x
|
-6.79
x
|
-11.1
x
|
-6.95
x
|
-3.63
x
|
-12.9
x
|
2.78
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.05
x
|
2.13
x
|
12.4
x
|
7.14
x
|
6.74
x
|
36.2
x
|
3.17
x
|
1.62
x
|
EV / Revenue
|
1.84
x
|
1.57
x
|
11.4
x
|
7.09
x
|
7.55
x
|
36.2
x
|
4.4
x
|
1.61
x
|
EV / EBITDA
|
9.09
x
|
-35.6
x
|
-6.42
x
|
-13.1
x
|
-8.83
x
|
-3.95
x
|
-4.81
x
|
2.97
x
|
EV / FCF
|
93.2
x
|
4.64
x
|
-6.12
x
|
-18
x
|
-7.45
x
|
-5
x
|
-5.32
x
|
2.26
x
|
FCF Yield
|
1.07%
|
21.5%
|
-16.4%
|
-5.57%
|
-13.4%
|
-20%
|
-18.8%
|
44.3%
|
Price to Book
|
0.81
x
|
0.94
x
|
-
|
-
|
3.79
x
|
10.5
x
|
-4.28
x
|
4.03
x
|
Nbr of stocks (in thousands)
|
14,767
|
14,926
|
17,920
|
18,259
|
18,488
|
21,569
|
21,569
|
-
|
Reference price
2 |
3.400
|
3.700
|
7.200
|
10.28
|
6.675
|
5.560
|
5.560
|
5.560
|
Announcement Date
|
3/28/19
|
3/26/20
|
3/26/21
|
3/30/22
|
4/27/23
|
3/27/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
24.46
|
25.95
|
10.43
|
26.31
|
18.3
|
2.227
|
37.83
|
73.93
|
EBITDA
1 |
4.963
|
-1.149
|
-18.56
|
-14.29
|
-15.65
|
-20.41
|
-34.6
|
40
|
EBIT
1 |
4.847
|
-1.472
|
-18.99
|
-16.62
|
-18.39
|
-22.98
|
6.434
|
45.96
|
Operating Margin
|
19.82%
|
-5.67%
|
-182.03%
|
-63.2%
|
-100.49%
|
-1,031.88%
|
17.01%
|
62.16%
|
Earnings before Tax (EBT)
1 |
4.707
|
-1.464
|
-19.25
|
-17.21
|
-18.02
|
-23.22
|
25.3
|
33.7
|
Net income
1 |
5.49
|
-4.652
|
-16.56
|
-16.85
|
-17.76
|
-23
|
-5.926
|
40.15
|
Net margin
|
22.45%
|
-17.93%
|
-158.69%
|
-64.05%
|
-97.04%
|
-1,032.91%
|
-15.66%
|
54.3%
|
EPS
2 |
0.3500
|
-0.3100
|
-1.060
|
-0.9300
|
-0.9600
|
-1.180
|
-0.4300
|
2.000
|
Free Cash Flow
1 |
0.484
|
8.799
|
-19.49
|
-10.39
|
-18.53
|
-30.7
|
-31.3
|
52.6
|
FCF margin
|
1.98%
|
33.9%
|
-186.8%
|
-39.5%
|
-101.22%
|
-1,023.33%
|
-82.73%
|
71.15%
|
FCF Conversion (EBITDA)
|
9.75%
|
-
|
-
|
-
|
-
|
-
|
-
|
131.5%
|
FCF Conversion (Net income)
|
8.82%
|
-
|
-
|
-
|
-
|
-
|
-
|
131.02%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/19
|
3/26/20
|
3/26/21
|
3/30/22
|
4/27/23
|
3/27/24
|
-
|
-
|
Fiscal Period: December |
2019 S1
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2023 S1
|
---|
Net sales
1 |
15.98
|
5.849
|
4.583
|
8.975
|
17.33
|
1.358
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-11.9
|
-11.58
|
-5.045
|
-
|
Operating Margin
|
-
|
-
|
-259.74%
|
-129.03%
|
-29.11%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-12.04
|
-11.76
|
-5.452
|
-
|
Net income
1 |
-
|
-
|
-13.44
|
-11.49
|
-5.362
|
-11.86
|
Net margin
|
-
|
-
|
-293.28%
|
-128%
|
-30.94%
|
-873.34%
|
EPS
2 |
0.0300
|
-0.2100
|
-0.8500
|
-0.6400
|
-0.2900
|
-0.6400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/5/19
|
9/17/20
|
3/26/21
|
9/21/21
|
3/30/22
|
9/27/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
14.7
|
33.7
|
46.6
|
-
|
Net Cash position
1 |
5.11
|
14.4
|
9.85
|
1.17
|
-
|
-
|
-
|
1.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.9397
x
|
-1.13
x
|
-1.347
x
|
-
|
Free Cash Flow
1 |
0.48
|
8.8
|
-19.5
|
-10.4
|
-18.5
|
-30.7
|
-31.3
|
52.6
|
ROE (net income / shareholders' equity)
|
9.37%
|
-7.73%
|
-27.6%
|
-
|
-44.1%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
4.220
|
3.930
|
-
|
-
|
1.760
|
0.5300
|
-1.300
|
1.380
|
Cash Flow per Share
2 |
0.0700
|
0.6100
|
-1.240
|
-0.5500
|
-
|
-0.1200
|
1.760
|
3.280
|
Capex
1 |
0.59
|
0.34
|
0.21
|
0.47
|
0.27
|
0.28
|
0.32
|
0.35
|
Capex / Sales
|
2.42%
|
1.29%
|
2.01%
|
1.79%
|
1.5%
|
9.44%
|
0.84%
|
0.47%
|
Announcement Date
|
3/28/19
|
3/26/20
|
3/26/21
|
3/30/22
|
4/27/23
|
3/27/24
|
-
|
-
|
Last Close Price
5.56
EUR Average target price
7.15
EUR Spread / Average Target +28.60% Consensus |
1st Jan change
|
Capi.
|
---|
| +29.91% | 128M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|